RX-3117

DRUG2 trials

Sponsors

Processa Pharmaceuticals

Conditions

Metastatic Bladder CancerMetastatic Pancreatic CancerSolid Tumor

Phase 1

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

CompletedNCT02030067

Processa PharmaceuticalsMetastatic Bladder Cancer, Solid Tumor

Start: 2013-12-31End: 2019-12-31Updated: 2023-12-06

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

CompletedNCT03189914

Processa PharmaceuticalsMetastatic Pancreatic Cancer

Start: 2017-10-02End: 2019-11-21Updated: 2023-12-06

Related Papers

Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with advanced urothelial cancer: Preliminary results of a phase IIa study.

Journal of Clinical Oncology2019-03-013 citations

A phase I/II study of RX-3117, an oral antimetabolite nucleoside, in combination with nab-paclitaxel (nab-pac) as first-line treatment of metastatic pancreatic cancer (met-PC): Preliminary results.

Journal of Clinical Oncology2019-01-295 citations

Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC).

Journal of Clinical Oncology2018-05-203 citations

RX‐3117, an oral hypomethylating agent to treat advanced solid tumors: Interim results from an ongoing phase 2a study in advanced urothelial cancer (aUC).

Journal of Clinical Oncology2018-02-20

RXÂ 3117: Activity of an oral antimetabolite nucleoside in subjects with pancreatic cancerâ€“Preliminary results of stage II of the phase Ia/IIb study.

Journal of Clinical Oncology2018-02-011 citations

Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ia/IIb study.

Journal of Clinical Oncology2017-05-20

Activity of RX-3117, an oral antimetabolite nucleoside, in patients with pancreatic cancer: Preliminary results of stage 1 of the phase 1a/2b.

Journal of Clinical Oncology2017-02-012 citations

Results of a phase 1 study of single agent RX-3117: An oral antimetabolite nucleoside to treat solid tumors.

Journal of Clinical Oncology2016-05-201 citations

A phase I study of RX-3117, an oral agent activated by uridine cytidine kinase 2, to treat subjects with advanced solid tumors.

Journal of Clinical Oncology2015-05-20